IPP Bureau

Cipla Technologies, Pulmatrix agree for development and commercialization of Pulmazole
Cipla Technologies, Pulmatrix agree for development and commercialization of Pulmazole

By IPP Bureau - January 08, 2024

Cipla shall now have exclusive rights for the development and commercialisation of Pulmazole in all countries except the United States of America

Mandaviya inaugurates CDSCO Sub Zonal Office and Central Drug Testing Laboratory in Indore
Mandaviya inaugurates CDSCO Sub Zonal Office and Central Drug Testing Laboratory in Indore

By IPP Bureau - January 08, 2024

Lays Foundation Stone of 6 new facilities at AIIMS Bhopal and inaugurates a slew of facilities in Madhya Pradesh

Pharmaids Pharmaceuticals to acquire Adita Bio Sys in share swap
Pharmaids Pharmaceuticals to acquire Adita Bio Sys in share swap

By IPP Bureau - January 07, 2024

The acquisition of the shares of Adita result in growth opportunities in line with strategic objectives of the company

Cipla EU to form JV in USA
Cipla EU to form JV in USA

By IPP Bureau - January 07, 2024

Menarini Group and Insilico Medicine ink agreement for Novel KAT6 inhibitor for treatment of breast cancer
Menarini Group and Insilico Medicine ink agreement for Novel KAT6 inhibitor for treatment of breast cancer

By IPP Bureau - January 07, 2024

This agreement includes upfront and milestone payments with a combined potential value of over $500m and sales royalties.

Omniose collaborates with AstraZeneca to research vaccines for serious bacterial diseases
Omniose collaborates with AstraZeneca to research vaccines for serious bacterial diseases

By IPP Bureau - January 07, 2024

Collaboration provides AstraZeneca with exclusive rights to Omniose’s proprietary bioconjugation platform to explore potential vaccines for a broad range of bacterial pathogens

AOB Pharma and Maruho enter into an agreement for AOB’s B244 for treatment of atopic dermatitis in Japan
AOB Pharma and Maruho enter into an agreement for AOB’s B244 for treatment of atopic dermatitis in Japan

By IPP Bureau - January 07, 2024

The deal includes upfront payments, milestone payments and ongoing royalties

Jiangsu Vcare files NDA for Vicagrel Capsules with USFDA
Jiangsu Vcare files NDA for Vicagrel Capsules with USFDA

By IPP Bureau - January 06, 2024

Merck announces Phase 3 trial initiations for 4 Investigational Candidates from hematology and oncology pipeline
Merck announces Phase 3 trial initiations for 4 Investigational Candidates from hematology and oncology pipeline

By IPP Bureau - January 06, 2024

Comprehensive clinical development programs being initiated for each investigational candidate

Servier and Base4 partner to advance neuroscience drug development
Servier and Base4 partner to advance neuroscience drug development

By IPP Bureau - January 06, 2024

Base4's drug discovery platform allows its collaborators to evaluate billions of novel small molecules to identify and progress RNA-modulators for important diseases

Supriya Lifesciences received GMP certification from ANVISA Brazil
Supriya Lifesciences received GMP certification from ANVISA Brazil

By IPP Bureau - January 06, 2024

The clearance of this audit marks the successful registration of 8 APIs with CADIFA

Hyderabad to host 66th All India Congress of Obstetrics and Gynaecology 2024
Hyderabad to host 66th All India Congress of Obstetrics and Gynaecology 2024

By IPP Bureau - January 05, 2024

The congress aims at emphasizing on the most recent trends, advancements in the field of Obstetrics & Gynaecology

PayNearby, Star Health join forces to provide health cover to uninsured across Bharat
PayNearby, Star Health join forces to provide health cover to uninsured across Bharat

By IPP Bureau - January 05, 2024

Star Health's convenient claims process, valued added offerings like free telemedicine consultations with expert doctors

Lupin receives tentative approval from USFDA for Dapagliflozin and Saxagliptin tablets
Lupin receives tentative approval from USFDA for Dapagliflozin and Saxagliptin tablets

By IPP Bureau - January 04, 2024

Dapagliflozin and Saxagliptin Tablets (RLD Qtern) had estimated annual sales of US $5 million in the US

CCRAS launches ‘SMART 2.0’ for ayurveda teaching professionals
CCRAS launches ‘SMART 2.0’ for ayurveda teaching professionals

By IPP Bureau - January 04, 2024

Latest Stories

Interviews

Packaging